Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Therapies: a Post Authorization Safety Study (PASS)
To assess the incidence of malignancies in severe asthma patients receiving benralizumab compared with those receiving non-benralizumab biologics, and those not receiving biologics.
To describe the clinical characteristics of the new malignancy cases that develop in severe asthma patients and relevant subgroups.